Hydralazine Amdipharm Uk Limited (Hydralazine Hydrochloride)

Hydralazine Amdipharm Uk Limited is indicated for use in several cardiovascular conditions where rapid reduction of blood pressure or improvement of cardiac output is required.

• Hypertension that is refractory to other oral agents.
• Acute decompensated congestive heart failure, especially when combined with other vasodilators.
• Hypertensive emergencies in a controlled clinical setting.
• Use as an adjunct in the management of severe pre‑eclampsia (off‑label, based on clinical practice).
• Preparation for certain cardiac surgeries to control hemodynamics.

• Hydralazine acts directly on the smooth muscle of arterioles by interfering with calcium influx and stimulating cyclic GMP pathways, which leads to relaxation of vascular smooth muscle. This vasodilation reduces systemic vascular resistance without significant effect on venous capacitance, thereby lowering arterial blood pressure. The drug’s action is independent of adrenergic receptors and does not rely on renal mechanisms, allowing rapid onset when given intravenously.

Adverse reactions to hydralazine can vary in frequency and severity.

Common

• Headache or flushing.
• Tachycardia or palpitations.
• Nausea, vomiting, or abdominal discomfort.
• Mild dizziness or light‑headedness.

Serious

• Lupus‑like syndrome with arthralgia and rash.
• Severe hypotension leading to syncope.
• Acute myocardial ischemia in susceptible patients.

Hydralazine should be used with careful clinical monitoring and consideration of patient‑specific factors.

• Assess baseline blood pressure and heart rate before initiation.
• Use cautiously in patients with coronary artery disease or recent myocardial infarction.
• Monitor for signs of drug‑induced lupus, especially with prolonged therapy.
• Adjust or discontinue if severe hypotension occurs.
• Avoid rapid intravenous bolus administration; prefer controlled infusion rates.
• Counsel patients about potential flushing and advise gradual position changes to reduce dizziness.

Hydralazine may interact with several medications, altering its efficacy or safety profile.

Avoid

• Concurrent use with other potent vasodilators (e.g., nitroglycerin) that may precipitate severe hypotension.
• Combination with beta‑blockers without careful titration, as reflex tachycardia may be blunted.
• Use with monoamine oxidase inhibitors (MAOIs) due to unpredictable blood pressure effects.

Use with caution

• Diuretics, which can enhance orthostatic hypotension.
• Calcium channel blockers, which may increase the risk of bradycardia.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs), which may reduce antihypertensive response.
• Immunosuppressants, as hydralazine‑induced lupus may be potentiated.